ANALYSIS DOXORUBICIN & DOXORUBICINOL IN DBS OF BREAST CANCER PATIENTS USING LC-MS:APPLICATION TO TDM

• At: AbuDhabi (United Arab Emirates) (2019)
• Type: Poster
• Poster code: POS-ASP-003
• By: HARAHAP, Yahdiana (Universitas Indonesia, Pharmacy, Indonesia)
• Co-author(s): Yahdiana Harahap: Pharmacy, Universitas Indonesia, Depok, Indonesia
  Sabrina Nur Amalia: Pharmacy, Universitas Indonesia, Depok, Indonesia
  Aldhi Anarta: Pharmacy, Universitas Indonesia, Depok, Indonesia
  Herman Suryadi: Pharmacy, Universitas Indonesia, Depok, Indonesia
  Ramadhan Ramadhan: Dharmais Cancer Hospital, Jakarta, Indonesia
  
• Abstract:

  Background

  The cardiotoxic effect of doxorubicin as first line chemotherapy agent of breast cancer is highly determined by accumulation of its main metabolite, doxorubicinol. Monitoring concentration of analyte and metabolite in DBS helps to prevent and minimize cardiotoxic effect by using ensuring appropriate dosage regiment with a more convenient

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login